Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...

Lung cancer can be treated with small molecules formulated as pills as well as biological medications that are injected or infused, both as standalone treatments or as part of drug combinations. A ...

Novocure has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the use of its portable Optune Lua device alongside PD-1/PD-L1 inhibitors to treat non-small cell lung ...

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...

CINCINNATI (WKRC) - A breakthrough device is providing new hope for brain cancer survivors, as demonstrated by the inspiring journey of Patty Young. Diagnosed with a brain tumor after suffering a ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...